Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon and Domainex Collaborate to Support Lead Optimization Oncology Program

Published: Tuesday, August 07, 2012
Last Updated: Tuesday, August 07, 2012
Bookmark and Share
Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds.

Horizon Discovery Ltd (Horizon) has announced that it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London.

Under the terms of the agreement, Horizon will profile a number of lead compounds against a panel of X-MAN™ isogenic disease model human cell lines, which accurately model the mutations found in cancer cells.

Profiling of Domainex’s lead TBK1/IKKe dual inhibitor molecules against the X-MAN cell lines will enable identification of the effect of individual mutations on drug activity and resistance and prediction of which patient sub-groups will respond.

This will help guide the medicinal chemistry optimization program and will provide important patient stratification data for future partnering.

“Horizon’s oncology and genome editing expertise are a valuable complement to our in-house biochemistry, medicinal chemistry and computer aided drug design capabilities,” commented Eddy Littler, CEO of Domainex.

Littler continued, “We look forward to working together to efficiently and cost-effectively develop a drug molecule for this important target. We also look forward to future collaborations with Horizon on Domainex’s epigenetic pipeline in oncology and with the wide number of projects that Domainex supports on behalf of its clients.”

Kam Dhaliwal, Director of Business Development, Horizon said: “We are delighted that Domainex has chosen to collaborate with Horizon on their lead program, and look forward to leveraging our Discovery Toolbox and Oncology expertise to help guide the program.”

Horizon’s Discovery Toolbox is based on its proprietary precision rAAV-mediated genome editing technology (GENESIS™), over 450 X-MAN human isogenic cell lines that more accurately model patient genetics (known as “patients in a test tube”), and 2D and 3D phenotypic assays.

The Toolbox enables the recapitulation of the patient situation in vitro and allows screening of the most important activated cancer genes and pathways found in patients, under conditions that mimic the micro environment of the disease.

Financial terms of the agreement are not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Announces Oncology Drug Discovery Collaboration with AstraZeneca
Agreement to explore Horizon’s first-in-class kinase target programme, HD-001.
Monday, April 22, 2013
Horizon and University of Leicester Form CoE in rAAV-mediated Genome Editing
Collaboration will focus on developing isogenic models of cardiovascular disease.
Monday, July 16, 2012
Horizon and H3 Biomedicine to Collaborate
H3 Biomedicine to employ Horizon’s unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics.
Friday, May 04, 2012
Horizon Announces Strategic Partnership with Promega
Partnership to combine Horizon’s genome editing technology with Promega’s reporter technologies to enable personalized drug development.
Tuesday, November 08, 2011
University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers
The collaboration will identify and validate novel cancer targets and biomarkers for personalized cancer therapy and diagnostics.
Monday, October 19, 2009
Horizon Discovery Sign Commercial Screening Agreement with Silicos
Agreement covers testing of Silicos lead compounds on human isogenic cell-lines comprising specific genotypes targeted by the compound series.
Tuesday, August 25, 2009
Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
License relates to the use of human isogenic cell-lines in predicting the response of drugs targeted at the genetic make-up of individual cancer patients.
Tuesday, August 11, 2009
Horizon Discovery Sign Screening Agreement with Actelion Pharmaceuticals
The agreement covers the screening of a number of Actelion lead compounds on a wide panel of genotypes using Horizon’s X-MAN cell-line technology.
Thursday, December 18, 2008
The X-MAN Steps-Out: Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
Horizon Discovery (Horizon) today announced it has signed two commercial agreements with a ground-breaking U.S. cancer start-up; Agios Pharmaceuticals (Agios), relating to its X-MAN technology.
Wednesday, October 01, 2008
Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
The agreements cover the licensing of certain X-MAN cell lines and the screening of a number of Agios lead compounds on a wide panel of genotypes.
Wednesday, October 01, 2008
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!